Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 669-684 , December 2006

Radioimmunotherapeutic strategies in autologous hematopoietic stem-cell transplantation for malignant lymphoma

  • David J. Inwards, MD (Associate Professor)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +1 507 284 4101.

REFERENCES 

  1. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [see comment] The New England Journal of Medicine. 2002;346(4):235–242
  2. Habermann TM, Weller EA, Morrison VA, et al. Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLDCL). Blood. 2003;102(11):6a
  3. Vose JM, Link BK, Grossbard ML, et al. Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leukemia & Lymphoma. 2005;46(11):1569–1573
  4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. [see comment] The New England Journal of Medicine. 1995;333(23):1540–1545
  5. Hahn T, Wolff SN, Czuczman M, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. Biology of Blood and Marrow Transplantation. 2001;7(6):308–331
  6. Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1996;14(4):1282–1290
  7. Seymour JF, Pro B, Fuller LM, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2003;21(11):2115–2122
  8. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–3732
  9. Rohatiner AZ, Gregory WM, Peterson B, et al. Meta-analysis to evaluate the role of interferon in follicular lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(10):2215–2223
  10. Hochster HS, Weller E, Ryan T, et al. Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2004;22(14_supplement):6502;(Meeting Abstracts)
  11. Schouten HC, Qian W, Kvaloy S, et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. [see comment] Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2003;21(21):3918–3927
  12. van Besien K, Loberiza FR, Bajorunaite R, et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003;102(10):3521–3529
  13. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(28):7013–7023
  14. Vose JM, Bierman PJ, Weisenburger DD, et al. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Biology of Blood and Marrow Transplantation. 2000;6(6):640–645
  15. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005;105(7):2677–2684
  16. Ganti AK, Bierman PJ, Lynch JC, et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2005;16(4):618–624
  17. Press OW. Radioimmunotherapy for non-Hodgkin's lymphomas: a historical perspective. Seminars in Oncology. 2003;30(2 supplement 4):10–21
  18. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1992;10(11):1696–1711
  19. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Research. 1995;55(23 supplement):5899s–5907s
  20. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1999;17(12):3793–3803
  21. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2002;20(15):3262–3269
  22. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. The New England Journal of Medicine. 1993;329(7):459–465
  23. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96(4):1259–1266
  24. Evens AM, Gordon LI. Radioimmunotherapy in non-Hodgkin's lymphoma: trials of yttrium 90-labeled ibritumomab tiuxetan and beyond. Clinical Lymphoma. 2004;5(supplement 1):S11–S15
  25. Vose JM. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma. Oncologist. 2004;9(2):160–172
  26. Knox SJ, Levy R, Miller RA, et al. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Research. 1990;50(16):4935–4940
  27. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1996;14(7):1974–1981
  28. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2000;18(6):1316–1323
  29. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. [see comment] Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2001;19(19):3918–3928
  30. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. [see comment] The New England Journal of Medicine. 2005;352(5):441–449
  31. Kaminski MS, Radford JA, Gregory SA, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(31):7985–7993
  32. Witzig TE. Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: a new treatment approach for B-cell non-Hodgkin's lymphoma. Drugs of Today (Barcelona, Spain: 1998). 2004;40(2):111–119
  33. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 1996;2(3):457–470
  34. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2002;20(10):2453–2463
  35. Witzig T, Wiseman G, Geyer S, et al. A phase I trial of two-sequential doses of ZevalinTM radioimmunotherapy for relapsed low-grade B-cell non-Hodgkin's lymphoma. Blood. 2003;102(11):406a
  36. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. [see comment] The New England Journal of Medicine. 1993;329(17):1219–1224
  37. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346(8971):336–340
  38. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1998;16(10):3270–3278
  39. Gopal AK, Rajendran JG, Gooley TA, et al. A Phase II Study of Myeloablative I-131-Anti CD-20 (Tositumomab) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Adults ≥60 Years of Age with High-Risk Relapsed or Refractory B-Cell Lymphoma. ASH Annual Meeting Abstracts. 2005;106(11):487
  40. Flinn IW, Kahl BS, Frey E, et al. Dose Finding Trial of Yttrium 90 (90Y) Ibritumomab Tiuxetan with Autologous Stem Cell Transplantation (ASCT) in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). ASH Annual Meeting Abstracts. 2004;104(11):897
  41. Vanazzi A, Ferrucci P, Ferrari M, et al. High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study. ASH Annual Meeting Abstracts. 2005;106(11):488
  42. Devizzi L, Seregni E, Guidetti A, et al. High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Minimal Toxicity and Full Feasibility in an Outpatient Setting. ASH Annual Meeting Abstracts. 2005;106(11):2737
  43. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. [see comment] Blood. 2000;96(9):2934–2942
  44. Vose JM, Bierman PJ, Enke C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23(3):461–467
  45. Nademanee A, Krishnan A, Fung H, et al. Yttrium 90 (90Y) ibritumomab tiuxetan in the treatment of non-Hodgkin's lymphoma (NHL): incorporation into autologous stem cell transplantation (ASCT) regimens. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2005;16(supplement 5):100
  46. Winter J, Inwards D, Spies S, et al. Zevalin (90YZ) doses >.5 mci/kg may be combined with high-dose BEAM and autotransplant (ASCT). Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO. 2005;16(supplement 5):100
  47. Nademanee A, Forman S, Molina A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood. 2005;106(8):2896–2902
  48. Gopal AK, Gooley TA, Maloney DG, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. [see comment] Blood. 2003;102(7):2351–2357
  49. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood. 2002;99(9):3158–3162
  50. Krishnan A, Raubitschek A, Forman SJ, et al. New Transplant Strategies Utilizing Radioimmunotherapy (RIT) Based Regimens To Reduce Relapse in High Risk Mantle Cell Lymphoma (MCL). ASH Annual Meeting Abstracts. 2005;106(11):681

PII: S1521-6926(06)00036-3

doi: 10.1016/j.beha.2006.05.004

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 669-684 , December 2006

Article Tools

* Image Usage & Resolution